Healthcare & Life Sciences

MultiSense Patch Reduces Hospital Stay After GI Surgery

The SENSE-ECO study is a prospective, randomized trial of 490 high-risk patients designed to show that the MultiSense® remote monitoring patch safely reduces hospital stays following major digestive surgery. By continuously tracking vital signs for five days at home, the device aims to maintain clinical safety and quality of life while decreasing overall healthcare costs for the French medical system. The study registration NCT07552805 was posted on April 27, 2026.

NCT07552480: Goserelin for Ovarian Preservation in Allo-HSCT Patients

This is a prospective, multicenter, randomized controlled clinical trial registered on ClinicalTrials.gov under identifier NCT07552480, evaluating goserelin for preservation of ovarian function in 64 female patients aged 14-50 with malignant hematologic diseases undergoing allogeneic hematopoietic stem cell transplantation. The study enrolled 64 patients divided by conditioning type (MAC vs. non-MAC), then randomized 1:1 within each group to receive a single 3.6 mg subcutaneous goserelin injection 1-3 days prior to conditioning or no goserelin. The primary endpoint is menstrual recovery rate at 6 months post-transplantation, with secondary endpoints including incidence of premature ovarian insufficiency, ovarian reserve markers (AMH, FSH, LH, E2), ovarian volume, and endometrial thickness.

Observational Study Uses AI for Dental, Orthodontic Imaging Analysis

This registry entry documents NCT07551622, an observational study evaluating deep learning-based AI models for craniomaxillofacial multi-modal imaging analysis in dentistry, orthodontics, and oral maxillofacial practice. The study plans to enroll approximately 2,000 participants, analyzing 2D facial photographs, cone-beam CT images, and 3D facial surface scans to support image classification, anatomical landmark detection, segmentation, abnormality recognition, and treatment-related decision-making. The AI models are explicitly designed as clinical decision-support tools and are not intended to replace professional diagnosis or individualized treatment planning.

Mobile App Versus Tell-Show-Do Technique for Pediatric Dental Anxiety in Karachi: Multicenter Randomized Controlled Trial

This registration documents a multicenter randomized controlled trial comparing a mobile application-based behavioral intervention versus the conventional tell-show-do (TSD) technique for managing dental anxiety in children aged 7-11 years attending their first dental visit at tertiary care dental hospitals in Karachi, Pakistan. Participants are randomly assigned to either intervention prior to a dental diagnostic procedure. The primary outcomes are changes in pulse rate and anxiety levels measured using the Raghavendra Madhuri Sujata Pictorial Scale (RMS-PS) before and after the intervention.

Disease Activity Monitoring in Patients With Giant Cell Arteritis Study

An observational clinical study (NCT07552636) registered on ClinicalTrials.gov evaluating tools for monitoring disease activity and predicting relapses in patients with Giant Cell Arteritis (GCA). The study will enroll up to 175 patients with GCA in remission, with a target of 144 participants completing 1 year of follow-up. Participants will undergo vascular ultrasonography with double-blinded relapse assessment, complete patient-reported outcome measures, and provide biobank blood samples.

Phase 3 NCT07552389 Trial: HL1113R1/R2 vs HL1113 in Hypertension and Diabetes

Phase 3 clinical trial NCT07552389 registered April 27, 2026, evaluating HL1113R1/R2 monotherapy versus HL1113 fixed-dose combination in patients with essential hypertension and type II diabetes mellitus. The multi-center, randomized, double-blind study will assess efficacy and safety across four intervention groups (test, exploratory test, and two control groups). Pharmaceutical manufacturers, clinical research organizations, and healthcare institutions involved in diabetes and cardiovascular research should monitor this trial for competitive intelligence and patient recruitment updates.

Phase 4 Acupuncture vs Medication for Anxiety and Depression in China

A new Phase 4 clinical trial (NCT07552246) has been registered comparing acupuncture against standard SSRI medication for treating anxiety and mild-to-moderate depression in adults in China. The study aims to identify the most cost-effective and environmentally sustainable intervention between the two approaches. Conditions studied include Anxiety and Depression, with interventions including Selective Serotonin Reuptake Inhibitor (SSRI) and Acupuncture as standalone comparators.

Michigan DHHS Launches Gun Lock Map, 150 Sites for Free Firearm Safety

The Michigan Department of Health and Human Services launched a new statewide Gun Lock Distribution Map identifying 150 locations where Michigan residents can obtain free cable-style gun locks. The free locks are provided by Michigan State Police through Project ChildSafe, a nationwide firearm safety initiative. Community organizations, health departments, local governments, and other partners can request to become distribution sites by completing an online survey and will receive locks shipped directly upon approval. MDHHS stated that safe firearm storage helps prevent unintentional shootings, youth access to firearms, and suicide.

Hepatitis Gains Made, 2030 Targets Need Acceleration

The 2026 Global Hepatitis Report documents measurable progress since 2015: hepatitis B new infections dropped 32% globally, hepatitis C deaths fell 12%, and 85 countries have achieved or surpassed the 2030 target of 0.1% hepatitis B prevalence in children under five. However, 287 million people were living with chronic hepatitis B or C in 2024, with only 5% of hepatitis B patients receiving treatment and just 20% of hepatitis C patients treated since 2015. The WHO Director-General noted that while elimination is achievable with sustained political commitment, urgent scale-up of prevention, diagnosis, and treatment is needed to meet 2030 targets.

WHO Convenes 26 Countries for Exercise Polaris II Simulated Disease Outbreak Response

WHO concluded Exercise Polaris II, a 2-day high-level simulation exercise on April 22–23, 2026, based on a fictional new bacterium spreading globally. The exercise engaged 26 countries and territories, 600 health emergency experts, and over 25 partners including Africa CDC, UNICEF, MSF, and the Global Outbreak Alert and Response Network. Participants activated emergency coordination structures, tested information-sharing protocols, and practiced workforce surging under real-life conditions, operationalizing two key WHO frameworks: the Global Health Emergency Corps (GHEC) framework (June 2025) and the National health emergency alert and response framework (October 2025).

Swedish MPA Positive on EU Biotech Proposal, Warns on Patient Safety

Läkemedelsverket (Swedish Medical Products Agency) has submitted its response to an EU consultation on proposed biotech regulation. The agency expresses conditional support for the EU proposal but warns that additional strengthening is needed to adequately protect patient safety. This positions Sweden among EU member states providing input on the draft regulation.

Läkemedelsverket på Vitalis 2026, Göteborg, 5-7 maj

Läkemedelsverket (Swedish Medical Products Agency) announces its participation in Vitalis 2026, an annual healthcare digitalization conference held at Svenska Mässan in Gothenburg, Sweden, May 5-7, 2026. The agency will host sessions covering drug logistics, clinical trials, responsible AI use in healthcare, European Health Data Space (EHDS), drug shortage prevention, and supervision of national medical information systems. The agency shares booth B07:17 with Socialstyrelsen, E-hälsomyndigheten, SKR, and Inera.

Semaglutid 476 Och Tirzepatid 382 Rapporter 2025

Läkemedelsverket (Swedish Medicines Agency) published 2025 adverse drug reaction statistics showing 12,615 total spontaneous reports received, stable from the prior year. Healthcare providers submitted 7,382 reports while private individuals submitted 5,233. Semaglutide (476 reports) and tirzepatide (382 reports) topped the list of most-reported substances, used for type 2 diabetes and weight control. The agency emphasized that most reports are classified as non-serious and involve known side effects, while noting increased prescribing as a contributing factor.

Phase 1 Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors

A prospective, open-label, exploratory Phase 1 clinical study (NCT07551778) evaluating the safety and preliminary efficacy of allogeneic natural killer (NK) cell injection combined with standard maintenance therapy across three cohorts: advanced non-squamous NSCLC, advanced colorectal adenocarcinoma, and a lymphodepletion exploration cohort. The trial enrolled patients with locally advanced or metastatic solid tumors as of April 27, 2026. This registry entry documents the study design and does not impose compliance obligations on any party.

Patient Reported Outcome Measurements Registration in Spinal Pathologies and Neuromodulation

A prospective observational clinical registry has been registered on ClinicalTrials.gov under identifier NCT07552519. The study will collect longitudinal data through questionnaires and categorical diagnostic and therapeutic registration for patients with spinal pathologies and neuromodulation. Conditions include Spinal Pathologies, Pain, Cervical Pain, Lumbar Pain Syndrome, Neurostimulation, and Disc Degenerative Disease. This registration is for informational purposes and does not impose any compliance obligations.

Effect of TMJ Arthrocentesis on Capsular Width: An Ultrasonographic Study

ClinicalTrials.gov registration for NCT07553078, a prospective cohort study at Van Yuzuncu Yil University, Turkey, evaluating the effect of temporomandibular joint arthrocentesis on articular capsular width using ultrasonography. The study received ethics approval (2025/02-07) from Van Yuzuncu Yil University Clinical Research Ethics Committee on February 28, 2025, and is registered as of April 27, 2026. Participants with unilateral intra-articular TMJ disorder receive arthrocentesis with sterile Ringer's lactate solution using a two-needle technique.

Injectable Bioactive Giomer Composite vs Hall Technique for Proximal Cavities in Primary Molars

A randomized clinical trial has been registered on ClinicalTrials.gov (NCT07552129) comparing the survival rate and clinical performance of injectable bioactive giomer composite restorations versus the Hall Technique for managing proximal carious lesions (ICDAS 3-4) in primary molars of children aged 3-8 years over a 12-month follow-up period. The study lists dental caries as the condition and giomer and Hall technique as the interventions under study. This registry entry documents the trial protocol and recruitment parameters for interested clinical investigators and institutional review boards.

Art-Based Intervention for Hematological Cancer Patients: Randomized Controlled Trial

A randomized controlled experimental study registered on ClinicalTrials.gov (NCT07551817) examining the effect of art-based intervention on fatigue, anxiety, perception of nurse presence, and quality of life in patients with hematological cancer. The study will enroll 52 patients split into intervention and control groups (26 each) at a training and research hospital Hematology department from May 2025 to October 2026. The intervention group receives art-based sessions three times per week for two weeks, while the control group receives no intervention. Data collection uses Patient Identifier Information Form, Cancer Fatigue Scale, FACT-G, HADS, and Nurse Presence Scale.

Goal Commitment and Proactive Health Behavior in Chronic Disease Patients

A behavioral intervention study registered on ClinicalTrials.gov (NCT07552571) will investigate how goal commitment theory, prospect theory, and evolutionary game theory explain the gap between knowledge and action in chronic disease patients. The parallel controlled trial will enroll patients with hypertension, diabetes mellitus, and dyslipidemia and compare a Stimulus-Organism-Response (SOR) model-based goal commitment intervention against usual care. No regulatory obligations or compliance requirements are imposed by this registry entry.

Random Controlled Trial of Home-Based Digital Therapy for ADHD in Children

NIH registered a new randomized controlled trial (NCT07552909) on ClinicalTrials.gov to evaluate the efficacy of home-based digital neurofeedback games as an intervention for school-aged children diagnosed with mild to moderate ADHD. The study will explore the effects of brain-controlled games on core ADHD symptoms. This registry entry establishes the formal study record and intervention protocol. No compliance obligations or enforcement actions are associated with this registration.

Daily Screen Time and Postoperative Delirium in Children Study

A prospective observational study (NCT07552896) registered with ClinicalTrials.gov on April 27, 2026, will examine the association between daily screen exposure duration and postoperative emergence delirium in 60 children aged 2 to 11 years undergoing elective lower abdominal surgery. The study will assess daily screen time via parent-reported questionnaire preoperatively and evaluate emergence delirium using the Pediatric Anesthesia Emergence Delirium scale at 5, 10, 15, and 30 minutes post-surgery.

Honey Bee Venom Immunotherapy Randomised Safety Study, Victoria

The Royal Melbourne Hospital has registered a Phase 0 randomised controlled pilot study comparing two honey bee venom immunotherapy (HBV-VIT) initiation strategies in adults sensitised to honey bee venom. The trial will enrol 24 participants at The Royal Women's Hospital (Parkville) and Monash Medical Centre (Clayton), Victoria, with anticipated first enrolment on 30 April 2026 and final data collection by 30 July 2027. Participants will be randomised to either direct 100-µg maintenance-dose initiation (weeks 0, 4, 8, 12) or ultrarush up-dosing (escalating doses over six weeks), with safety monitoring for systemic and local reactions across the 12-week induction period. The study aims to quantify immunologic changes (HBV-specific sIgE/sIgG4), blood tryptase, late-phase symptoms, and quality-of-life outcomes.

Osteopathy Versus Physiotherapy for Chronic Low Back Pain, Warsaw Poland

ANZCTR registration ACTRN12626000521325 for a completed comparative effectiveness trial conducted entirely in Warsaw, Poland, comparing osteopathic manual therapy versus conventional physiotherapy for non-specific chronic lumbosacral pain. The trial enrolled 84 participants (target 102), was approved by the Bioethics Committee of the Medical University of Warsaw on 15/04/2014, and was retrospectively registered on 28/04/2026 after data collection concluded on 25/02/2022. No individual participant data will be shared as the survey was conducted anonymously.

Deadly Fit Mums Exercise Program for Indigenous Mothers

The Deadly Fit Mums (DFM) program is an Aboriginal community-led exercise and nutrition education program registered as a clinical trial on ANZCTR (ACTRN12626000522314). The program serves pregnant and post-partum women birthing an Aboriginal and Torres Strait Islander baby through the Birthing in Our Community (BiOC) service across four sites in South East Queensland. The primary sponsor is Federica Barzi at the University of Queensland, with the Institute for Urban Indigenous Health as a collaborator and funding from the Australian Government Department of Health Medical Research Future Fund. Ethics approval was granted by The University of Queensland Human Research Ethics Committee (2025/HE000966) on 18/06/2025. The trial is registered retrospectively with enrollment of 1,300 participants completed between January 2023 and June 2025, and final data collection anticipated by June 2026.

Effect of Spinal and General Anesthesia on Frontal QRS Axis in Total Knee Arthroplasty

NIH registered study NCT07551648, a prospective observational trial comparing frontal QRS axis changes in patients undergoing total knee arthroplasty under spinal versus general anesthesia. The study will enroll adults aged 18 years and older with ASA physical status I to III, using standard 12-lead electrocardiography to measure preoperative-to-postoperative QRS axis changes. Enrollment criteria, methodology, and outcome measures are now publicly available on ClinicalTrials.gov for research transparency purposes.

Pilot Validation of STELA Digital Preventive Medicine Platform for Cardiovascular Risk Reduction in Adults

A pilot validation study for the STELA digital preventive medicine platform has been registered on ClinicalTrials.gov (NCT07551960) by researchers at AGEL Hospital Trinec-Podlesi in Czechia. The platform is designed to identify, quantify, and reduce modifiable cardiovascular health risk factors in adults without established cardiovascular disease through comprehensive health assessments, personalized prevention plans, and coordinated wellness interventions. The study uses the AGEL Gamification Index scoring system and involves participants undergoing extensive baseline assessments including laboratory panels, physical tests, and imaging studies.

Novel MRI Sequences for Prostate Cancer Diagnosis Accuracy: NCT07552285

NCT07552285 is a prospective observational study registered at a single center evaluating the diagnostic efficacy and grading accuracy of novel MRI sequences (MAGiC, OGSE, CEST, IVIM) for prostate cancer detection. The study enrolls patients with clinical suspicion of prostate cancer and performs both conventional and new sequence magnetic resonance scans, using surgical or biopsy pathological results as the gold standard for comparison. The primary research question is whether novel non-contrast multiparametric MRI imaging can improve accuracy of prostate cancer diagnosis and grading compared to conventional approaches.

Goserelin Preserves Ovarian Function in Aplastic Anemia Following Allogeneic HSCT

This ClinicalTrials.gov registration documents NCT07552506, a prospective randomized multicenter clinical trial investigating whether Goserelin prophylaxis preserves ovarian function in 132 female patients aged 14-50 with severe aplastic anemia undergoing allogeneic hematopoietic stem cell transplantation. Patients will be stratified by busulfan conditioning status and randomized 1:1 to receive a single 3.6 mg subcutaneous Goserelin injection 1-3 days prior to conditioning or standard transplantation regimen without Goserelin. The primary endpoint is menstrual recovery rate at 6 months post-transplant, defined as at least 3 naturally occurring menstrual cycles without intervention by menstrual-regulating drugs.

Astragalus Membranaceus 480mg/day 10-Week Muscle Function Study NCT07552675

This double-blind, placebo-controlled, randomized clinical trial (NCT07552675) evaluated whether daily supplementation with Astragali radix extract (480 mg/day) for 10 weeks could attenuate training-induced impairments in muscle function, joint pain, and inflammatory markers in moderately active young adults during 8 weeks of progressive resistance training followed by 2 weeks of intensified training. Participants were randomized to receive either the herbal extract or placebo, with primary outcome measured as maximal voluntary isometric torque (MVIT) of the knee extensors and secondary outcomes including 1RM strength, knee range of motion, muscle soreness, and circulating biomarkers of muscle damage and inflammation. The study record was processed and made publicly available on ClinicalTrials.gov.

Trapeziometacarpal Joint Arthroplasty Versus Trapeziectomy for Thumb Carpometacarpal Osteoarthritis RCT

Sahlgrenska University Hospital in Gothenburg, Sweden has registered a single-centre, blinded randomized controlled trial comparing trapeziometacarpal prosthetic arthroplasty versus trapeziectomy for symptomatic thumb carpometacarpal osteoarthritis in adults aged 18-69 years with Eaton grade 2-3 disease refractory to 3 months of non-operative treatment. The target enrollment is 64 participants randomized 1:1, with primary outcome of day-by-day pain measured on a numeric rating scale (NRS 0-10) and follow-up extending to 10 years.

CABG Trial Comparing Radial Artery vs No-Touch Vein Graft in Women

A randomized controlled trial comparing outcomes of coronary artery bypass grafting (CABG) in women at 1 year post-surgery has been registered on ClinicalTrials.gov under identifier NCT07552948. The main group includes 55 patients receiving CABG with radial artery grafts, while the control group includes 55 patients receiving CABG with great saphenous vein prepared using the no-touch technique, both for revascularization of the circumflex artery. The study examines the condition of coronary artery atherosclerosis.

Adapted RPM-08 for Substance Use Disorder in Pakistan

This ClinicalTrials.gov registration (NCT07552623) describes an eight-week randomized controlled trial in Pakistan testing whether a culturally adapted Relapse Prevention Module (RPM-08) combined with usual treatment reduces relapse risk in adults with substance use disorders, compared to usual treatment alone. Participants will attend eight structured group sessions and complete questionnaires at baseline, post-intervention, and follow-up to assess whether the adapted intervention's effects are sustained over time. This trial registration provides study design and participant information but does not impose compliance obligations on regulated entities.

Clinical Performance of Laryseal Clear vs Ambu Aura40 Laryngeal Mask Airway for Preschool Children

A clinical trial comparing the performance of Laryseal Clear and Ambu Aura40 laryngeal mask airways in preschool children undergoing surgical procedures has been registered on ClinicalTrials.gov. The study will evaluate both devices as supraglottic airway devices in pediatric anesthesia settings. NCT07553247 was registered on April 27, 2026, and the trial will assign participants to either the LarySeal clear Group or the Ambu Aura40 Group.

Low Intensity Laser Therapy Study, Children, Pneumonia

Clinical trial NCT07552116 registered on ClinicalTrials.gov evaluates whether low intensity laser therapy combined with standard medical treatment improves immune response in children with Down syndrome (DS) and pneumonia. The randomized controlled study enrolled 40 DS children with bronchopneumonia, assigning 20 to receive low intensity laser therapy three times weekly for one month alongside inspiratory muscle training and medical treatment. Both groups had immune system markers (WBCs, IgG, IgA, IgM), respiratory rate, and oxygen saturation measured before and after the one-month treatment period.

Ponlimsi Biosimilar to Prolia Approved March 2026

Ponlimsi Biosimilar to Prolia Approved March 2026

CAPTIVATE Trial Diet Microbiome Triple Negative Breast Cancer

The NIH has registered NCT07551765, the CAPTIVATE trial, a multi-center observational study examining the impact of diet-driven gut microbiome on treatment outcomes in women with untreated, stage I-III Triple Negative Breast Cancer undergoing neoadjuvant treatment with and without immune checkpoint inhibitors. The trial will collect stool samples, core tumor biopsies, and research blood samples at various study timepoints for analysis. As an observational registry entry, this posting does not impose compliance obligations on regulated entities.

ANKTIVA Plus BCG Versus BCG Monotherapy in High-Grade Non-Muscle Invasive Papillary Bladder Cancer, Phase 3 Study

NIH registered a Phase 3 clinical trial (NCT07551544) on April 27, 2026, evaluating intravesical ANKTIVA (400µg) plus BCG (50mg) against BCG monotherapy (50mg) in participants with histologically confirmed BCG-naïve or BCG-exposed high-grade Ta/T1 papillary non-muscle invasive bladder cancer. The open-label, randomized study will assess the contribution of ANKTIVA as an experimental neoadjuvant therapy in papillary NMIBC.

NK Cell Therapy for Malignant Solid Brain Tumors

A multi-center, open-label investigator-initiated trial (IIT) registered on ClinicalTrials.gov evaluating the safety, tolerability, and feasibility of combined intracranial and intravenous administration of ex vivo expanded and activated natural killer (NK) cells in adult patients with malignant solid brain tumors who have failed standard treatment modalities. The primary objective is to determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of the combined NK cell therapy. Secondary objectives include preliminary assessment of anti-tumor activity as measured by progression-free survival (PFS), overall survival (OS), objective response rate (ORR) per RANO criteria, and evaluation of immunological effects.

Lidocaine Infusion Reduces Opioid Requirements in Children - Phase 4 Trial NCT07552766

NIH registered a Phase 4 clinical trial (NCT07552766) on April 27, 2026 to evaluate whether intraoperative intravenous lidocaine infusion reduces total perioperative opioid requirements in 90 pediatric patients ages 3-18 undergoing surgical fixation of upper extremity long bone fractures. The prospective, randomized, double-blind trial enrolls participants 1:1 to receive either IV lidocaine or placebo (normal saline) during surgery under general anesthesia. The primary outcome measures total opioid consumption 60 minutes after arrival to the post-anesthesia care unit (PACU), with secondary outcomes including opioid use at additional time points, postoperative pain scores, PACU length of stay, rescue antiemetic use, and relationship between infusion duration and outcomes.

Observational Study on Pleasant Touch in Chronic Pain

NIH has registered a new observational study (NCT07551687) examining pleasant touch perception in individuals with chronic pain and its association with central sensitization and interoceptive awareness. Participants will be recruited from a specialist Pain Clinic in Västra Götaland, Sweden, and will complete online questionnaires assessing pain, touch experience, interoceptive awareness, and central sensitization. The study aims to compare pleasant touch perception across different pain mechanism types: nociceptive, neuropathic, and nociplastic.

Oxygen Modulator Hypoxic/Hyperoxic Tabata Training Study

NIH registered a clinical trial (NCT07551869) examining how breathing air with different oxygen concentrations during high-intensity interval training (Tabata protocol) affects aerobic capacity, ventilatory thresholds, blood lactate levels, and perceived exertion. The three-week study will enroll participants randomly assigned to breathe hyperoxic or hypoxic air during training sessions. This is a research study registry entry with no compliance obligations.

Full-Wrap vs Double-Strap Suspension for Reducing Soft Palate Injury: Multi-Center RCT

The National Institutes of Health registered NCT07552545, a prospective multi-center randomized controlled trial comparing full-wrap suspension versus traditional double-strap suspension for reducing soft palate injury during transoral and transnasal pharyngeal surgery. The study enrolls patients with adenoid hypertrophy, tonsillar hypertrophy, nasopharyngeal diseases, nasopharyngeal tumors, parapharyngeal or skull base lesions, or conditions requiring soft palate suspension. The registry entry was posted April 27, 2026.

NCT07552467: LRRC15 PET Imaging for GI Tumor Diagnosis Study

NIH ClinicalTrials.gov has registered an observational study (NCT07552467) evaluating LRRC15-specific PET radiotracers as targeted imaging agents for diagnosis and staging across eight malignant tumor types: pancreatic cancer, breast cancer, lung cancer, sarcoma, head and neck tumors, glioblastoma, colorectal cancer, and melanoma. The study will enroll both patients and healthy volunteers, comparing LRRC15 PET imaging against histopathological diagnosis and against existing agents [18F]FDG PET and [68Ga]Ga-FAPI PET to evaluate diagnostic efficacy and facilitate therapeutic decision-making.

Ripretinib Recommended for Advanced GIST After Kinase Inhibitors

NICE has published final technology appraisal TA1146 recommending ripretinib (Qinlock) for NHS use in adults with advanced gastrointestinal stromal tumours (GIST) who have received three or more kinase inhibitors. This guidance updates and replaces the prior recommendation TA881, reflecting new evidence reviewed on 28 April 2026. NHS commissioners and providers are required to fund ripretinib within three months of the publication date in accordance with NHS Constitution obligations.

12-Week PFMT With Imagery for Geriatric Urinary Incontinence

A clinical trial (NCT07551674) registered on ClinicalTrials.gov investigates the effects of a 12-week Pelvic Floor Muscle Training (PFMT) program using Action Observation Therapy (AOT) with metaphorical imagery on urinary incontinence in geriatric women aged 65 and older. The study, to be conducted between June 2025 and June 2026 in nursing homes in Istanbul, will enroll participants with stress or stress-predominant mixed urinary incontinence and normal cognitive function. Both study groups will undergo twice-weekly 45-50 minute progressive exercise sessions advancing from supine positions to standing and jumping movements, with the AOT group additionally observing metaphor-themed projected visuals. Efficacy will be evaluated using standardized tools including the Pelvic Floor Distress Inventory-20, 24-hour pad test, and Incontinence Quality of Life Scale.

Clinical Trial Tests AI Symptom Analysis via Pre-Visit Lab

NIH registered a new experimental clinical trial (NCT07552311) titled 'Generative AI Plan for Care Lab Study' on April 27, 2026. The study will observe participants' interactions with generative AI models designed to respond to consumer symptom queries, providing information about possible urgency, potential causes or diagnoses, and a summary of information to bring to a healthcare visit. The trial involves Fitbit Plan for Care Lab and Baseline Model interventions targeting Primary Health Care conditions.

Comparison of 3D Printed Resin Fixed Mandibular Retainer Versus Conventional Fixed Bonded Retainer

NIH ClinicalTrials.gov registered study NCT07552155 on April 27, 2026, comparing 3D printed resin fixed mandibular retainers to conventional fixed bonded retainers. The clinical trial will evaluate bond pair conditions across both intervention types, addressing a noted gap in evidence regarding chair side time and bond failure rates for 3D printed fixed mandibular retainers. This trial registration adds to the growing body of orthodontic research on digital manufacturing applications in dental retention therapy.

RCT Evaluates ChatGPT Teaching Model for Nursing Pain Management

Shahid Beheshti University of Medical Sciences (Tehran, Iran) is conducting a two-arm parallel-group randomized controlled trial (RCT) to evaluate the effect of a ChatGPT-driven blended teaching model on nursing students' knowledge, attitudes, competence, and learning self-efficacy in pain management. Eligible nursing students will be randomly assigned 1:1 to either the intervention group (ChatGPT-assisted blended clinical nursing rounds, 8 sessions over 4 weeks, each 90 minutes) or the control group (traditional clinical nursing rounds with no AI tools). Outcomes will be measured at baseline, immediate post-test, and 3-month follow-up using validated instruments including NKASRP, NSCS, and NLSE. This is a prospective clinical trial registration; no compliance obligations or regulatory actions are associated with this document.